Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) Equity Average (2020 - 2025)

Historic Equity Average for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $98.6 million.

  • Pulse Biosciences' Equity Average rose 8584.45% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.6 million, marking a year-over-year increase of 8584.45%. This contributed to the annual value of $79.6 million for FY2024, which is 27809.18% up from last year.
  • Latest data reveals that Pulse Biosciences reported Equity Average of $98.6 million as of Q3 2025, which was up 8584.45% from $111.5 million recorded in Q2 2025.
  • Pulse Biosciences' Equity Average's 5-year high stood at $116.7 million during Q1 2025, with a 5-year trough of -$6.5 million in Q1 2023.
  • Moreover, its 5-year median value for Equity Average was $40.3 million (2024), whereas its average is $47.6 million.
  • Data for Pulse Biosciences' Equity Average shows a peak YoY increase of 234874.4% (in 2023) and a maximum YoY decrease of 11982.32% (in 2023) over the last 5 years.
  • Over the past 5 years, Pulse Biosciences' Equity Average (Quarter) stood at $45.9 million in 2021, then tumbled by 95.7% to $2.0 million in 2022, then soared by 2348.74% to $48.3 million in 2023, then skyrocketed by 101.02% to $97.0 million in 2024, then grew by 1.64% to $98.6 million in 2025.
  • Its Equity Average was $98.6 million in Q3 2025, compared to $111.5 million in Q2 2025 and $116.7 million in Q1 2025.